RxDoctor Payments Data

Sharon Winter

Family · Linwood, PANPI 1255518411

Payments from drug & device makers

$6,612in general payments, 2019–2025

Across 353 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$920
  • AbbVie$906
  • Pfizer$694
  • Corium, LLC$692
  • AstraZeneca$486
  • GSK$416
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$6,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,612 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,612
Medicare patients
165
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$14,494
JanuviaSitagliptin Phosphate12$14,335
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,564
Atorvastatin Calcium150$2,585
Rosuvastatin Calcium112$2,305
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,821
SynthroidLevothyroxine Sodium12$1,534
Levothyroxine Sodium98$1,310
Omeprazole91$1,296
Ventolin HfaAlbuterol Sulfate11$1,157
Hydroxyzine Hcl15$960
Losartan Potassium84$944
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16$920
Escitalopram Oxalate40$891
Albuterol Sulfate HfaAlbuterol Sulfate28$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$920$14,49412 claims
GSKAnoro Ellipta$416$10,56416 claims
AbbVieSynthroid$906$1,53412 claims
Almatica Pharma LLCSertraline Hcl$74$71044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Linwood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →